According to @StockMKTNewz, Eli Lilly (LLY) and Nvidia (NVDA) announced a partnership to build what the companies describe as the most powerful supercomputer run by a pharmaceutical company to boost the discovery of new medicines, as reported in The Wall Street Journal via the cited post. Source: @StockMKTNewz post on X dated Oct 28, 2025; The Wall Street Journal as cited by @StockMKTNewz. This headline establishes a tangible AI-compute catalyst tied to drug discovery workflows for both LLY and NVDA, with the core claim being the build-out of the most powerful pharma-run supercomputer and its stated aim to accelerate medicine discovery. Source: @StockMKTNewz post on X dated Oct 28, 2025; The Wall Street Journal as cited by @StockMKTNewz. No additional specifications, capex details, or deployment timelines were provided in the cited post beyond the claim of building the most powerful pharma-operated supercomputer for boosting drug discovery. Source: @StockMKTNewz post on X dated Oct 28, 2025.